Tyrosine kinase inhibitors: What after complete remission of lung cancer?

Abstract Lung cancer is one of the leading cause of cancer death globally; claiming the lives of the majority of patients afflicted by it. Targeted therapies especially Tyrosine Kinase Inhibitor (TKIs) are widely used treatment option for this fatal disease with intriguing mechanism of action and many lessons being learned from them. The current practice is to continue TKI indefinitely as long as there is no diease progression or unacceptable toxicity. Therefore, stopping EGFR TKI is not the standard of treatment. However, our patient insisted on stopping TKI after five years of treatment and she remained disease free. Three years after stopping the medication. This case raise a question about the indefinite use of TKI in all patients.